ORION CORPORATION
MANAGERS’ TRANSACTIONS
27 FEBRUARY 2025 at 11.00 EET
Orion Corporation: Managers’ transactions – Hao Pan
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Corporation – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Hao Pan
Position: Other senior manager
Issuer: Orion Corporation
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 98009/5/6
____________________________________________
Transaction date: 2025-02-26
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 2280 Unit price: 54.32603 EUR
Aggregated transactions (1):
Volume: 2280 Volume weighted average price: 54.32603 EUR
____________________________________________
Transaction date: 2025-02-26
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 2320 Unit price: 54.30367 EUR
Aggregated transactions (1):
Volume: 2320 Volume weighted average price: 54.30367 EUR
____________________________________________
Transaction date: 2025-02-26
Venue: OFF-EXCHANGE LIIKETOIMET (XOFF)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 2050 Unit price: 54.40011 EUR
Aggregated transactions (1):
Volume: 2050 Volume weighted average price: 54.40011 EUR
____________________________________________
Transaction date: 2025-02-26
Venue: LONDON STOCK EXCHANGE (XLON)
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details
(1): Volume: 2000 Unit price: 54.56 EUR
Aggregated transactions (1):
Volume: 2000 Volume weighted average price: 54.56 EUR
Orion Corporation
| Liisa Hurme
President and CEO |
Olli Huotari
Executive Vice President, |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orionpharma.com
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion’s net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
